To receive your instant CME certificate, you must first "Sign In" or "Sign Up" in the top right corner.
RELEASE DATE: June 1, 2020
EXPIRATION DATE: June 30, 2021
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™
CLICK HERE TO PROCEED TO PROGRAM
LEARNING METHOD AND MEDIUM
This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.
ACTIVITY DESCRIPTION
Dry eye disease (DED) is increasing in prevalence among people of all ages, and the use of digital devices is a major contributor to this trend. Diagnosis and treatment of DED is important to limit its deleterious consequences, which can include reduced visual function, decreased quality of life, and worse outcomes after cataract and refractive surgery. The desired results of this activity are for ophthalmologists to have a better understanding of the epidemiology of DED, screening techniques, advances in diagnostic testing, and approaches to individualized management.
TARGET AUDIENCE
This educational activity is intended for ophthalmologists.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be better able to:
- Review the epidemiology of DED
- Recognize the quality of life burden of DED
- Select appropriate diagnostic tests for evaluating DED
- Review the implications of inflammation in DED on treatment
- Apply evidence of DED treatments for individualized care of patients
ACCREDITATION STATEMENT
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.AMA CREDIT DESIGNATION STATEMENT
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
GRANTOR STATEMENT
This continuing medical education activity is supported through an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
DISCLOSURE POLICY STATEMENT
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
DISCLOSURES
Alice T. Epitropoulos, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Receipt of Intellectual Rights/Patent Holder: EpiGlare Tester; Consultant/Advisory Board: Abbott Medical Optics; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; Bruder Healthcare; Dompé US, Inc; EyePoint Pharmaceuticals; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Ocular Therapeutix, Inc; Omeros Corporation; Physician Recommended Nutriceuticals; and Sun Pharmaceutical Industries; Contracted Research: Bausch & Lomb Incorporated; Kala Pharmaceuticals, Inc; Ocular Therapeutix, Inc; Physician Recommended Nutriceuticals; and TearLab Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Abbott Medical Optics; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; Dompé US, Inc; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Ocular Therapeutix, Inc; Physician Recommended Nutriceuticals; and Sun Pharmaceutical Industries, Inc.
Marjan Farid, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Bio-Tissue; CorneaGen; Dompé US, Inc; EyePoint Pharmaceuticals; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals, Inc; and Shire.
Terry Kim, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Avedro, Inc; Avellino Labs; Bausch & Lomb Incorporated; BlephEx; CorneaGen; Dompé farmaceutici SpA; Eyenovia, Inc; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals, Inc; NovaBay Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Ocular Therapeutix, Inc; Omeros Corporation; Presbyopia Therapies; Shire; Sight Sciences; Surface Pharmaceuticals Inc; and Zeiss; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Avellino Labs; CorneaGen; Eyenovia, Inc; Kala Pharmaceuticals, Inc; NovaBay Pharmaceuticals, Inc; Ocular Therapeutix, Inc; Omeros Corporation; and Presbyopia Therapies.
Christopher E. Starr, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Bausch & Lomb Incorporated; BlephEx; Bruder Healthcare; Dompé farmaceutici SpA; Eyevance; EyePoint Pharmaceuticals; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals, Inc; Novaliq GmbH Germany; Novartis Pharmaceuticals Corporation; Quidel Corporation; Shire; Sight Sciences; Sun Pharmaceutical Industries, Inc; TearLab Corporation; and Verily Life Sciences LLC; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): TearLab Corporation.
NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PEER REVIEW DISCLOSURE
Priti Batta, MD, has no relevant commercial relationships to disclose.
EDITORIAL SUPPORT DISCLOSURES
Cheryl Guttman Krader; Melissa Carter-Ozhan, MS; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
DISCLOSURE ATTESTATION
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
OFF-LABEL DISCUSSION
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
https://www.nyee.edu/education/cme
CME Provider Contact Information
For questions about this activity, call 212-870-8125.
TO OBTAIN AMA PRA CATEGORY 1 CREDIT™
To obtain AMA PRA Category 1 Credit™ for this activity, read the material in its entirety and consult referenced sources as necessary. Please take the post test and evaluation online. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Novartis Pharmaceuticals Corporation, or Ophthalmology Times.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 214